RxDoctor Payments Data

Alan Kogan, MD

Cardiovascular Disease · Evanston, ILNPI 1821057498

Payments from drug & device makers

$1,163in general payments, 2019–2025

Across 50 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$342
  • Boehringer Ingelheim$204
  • Johnson & Johnson$112
  • Alnylam Pharmaceuticals Inc.$105
  • Pfizer$101
  • E.r. Squibb & Sons, L.L.C.$96
  • plus $204 from 6 others

What the payments were for

  • Food & beverage$1,15199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,163 in reported general payments places this provider in the 40th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$107,247
Medicare patients
468
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$366,434
EntrestoSacubitril/Valsartan148$182,707
XareltoRivaroxaban69$85,844
JardianceEmpagliflozin48$58,230
MounjaroTirzepatide37$39,475
RybelsusSemaglutide17$37,061
Repatha SureclickEvolocumab41$31,129
BrilintaTicagrelor13$14,901
CorlanorIvabradine Hcl12$12,664
Praluent PenAlirocumab18$11,803
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$7,817
Metoprolol Succinate348$5,734
Ezetimibe186$5,419
Atorvastatin Calcium341$4,025
ClopidogrelClopidogrel Bisulfate255$3,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$101$366,434270 claims
NovartisEntresto$342$182,707148 claims
Johnson & JohnsonXarelto$112$85,84469 claims
Boehringer IngelheimJardiance$204$58,23048 claims
AstraZenecaBrilinta$67$14,90113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Evanston

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →